Vertex Pharmaceuticals (VRTX) Competitors

$435.17 +5.35 (+1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$435.00 -0.17 (-0.04%)

As of 05:01 PM Eastern

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

Should you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), and Intuitive Surgical (ISRG).

How does Vertex Pharmaceuticals compare to Amazon.com?

Amazon.com (NASDAQ:AMZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Amazon.com currently has a consensus target price of $313.09, suggesting a potential upside of 16.39%. Vertex Pharmaceuticals has a consensus target price of $555.17, suggesting a potential upside of 27.58%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amazon.com.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	56 Buy rating(s)	0 Strong Buy rating(s)	2.95
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85

Amazon.com has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amazon.com's net margin of 12.22%. Vertex Pharmaceuticals' return on equity of 23.86% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amazon.com	12.22%	19.92%	9.86%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

In the previous week, Amazon.com had 267 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 321 mentions for Amazon.com and 54 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.88 beat Amazon.com's score of 0.79 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amazon.com	178 Very Positive mention(s)	63 Positive mention(s)	33 Neutral mention(s)	29 Negative mention(s)	11 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amazon.com	$716.92B	4.04	$77.67B	$8.36	32.18
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81

72.2% of Amazon.com shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 8.9% of Amazon.com shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Amazon.com on 9 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Vertex Pharmaceuticals currently has a consensus target price of $555.17, suggesting a potential upside of 27.58%. Axsome Therapeutics has a consensus target price of $251.26, suggesting a potential upside of 16.07%. Given Vertex Pharmaceuticals' higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Axsome Therapeutics' net margin of -26.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Vertex Pharmaceuticals had 15 more articles in the media than Axsome Therapeutics. MarketBeat recorded 54 mentions for Vertex Pharmaceuticals and 39 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.88 beat Axsome Therapeutics' score of 0.23 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	29 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	13 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81
Axsome Therapeutics	$708.24M	15.73	-$183.17M	-$3.73	N/A

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.

Vertex Pharmaceuticals currently has a consensus target price of $555.17, suggesting a potential upside of 27.58%. CRISPR Therapeutics has a consensus target price of $66.06, suggesting a potential upside of 22.32%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Vertex Pharmaceuticals had 14 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 54 mentions for Vertex Pharmaceuticals and 40 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.88 beat CRISPR Therapeutics' score of 0.38 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	29 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals has a net margin of 35.51% compared to CRISPR Therapeutics' net margin of -13,856.54%. Vertex Pharmaceuticals' return on equity of 23.86% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alphabet (NASDAQ:GOOG) are related large-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 27.3% of Alphabet shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of Alphabet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Alphabet has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.

Vertex Pharmaceuticals currently has a consensus target price of $555.17, suggesting a potential upside of 27.58%. Alphabet has a consensus target price of $362.73, suggesting a potential downside of 6.21%. Given Vertex Pharmaceuticals' higher possible upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than Alphabet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85
Alphabet	0 Sell rating(s)	4 Hold rating(s)	28 Buy rating(s)	6 Strong Buy rating(s)	3.05

In the previous week, Alphabet had 161 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 215 mentions for Alphabet and 54 mentions for Vertex Pharmaceuticals. Alphabet's average media sentiment score of 0.97 beat Vertex Pharmaceuticals' score of 0.88 indicating that Alphabet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	29 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alphabet	145 Very Positive mention(s)	14 Positive mention(s)	33 Neutral mention(s)	15 Negative mention(s)	5 Very Negative mention(s)	Positive

Alphabet has a net margin of 37.92% compared to Vertex Pharmaceuticals' net margin of 35.51%. Alphabet's return on equity of 38.99% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Alphabet	37.92%	38.99%	27.41%

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Alphabet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81
Alphabet	$422.50B	11.07	$132.17B	$13.11	29.50

Summary

Alphabet beats Vertex Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Vertex Pharmaceuticals has higher revenue and earnings than Intuitive Surgical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	14.78	$2.86B	$8.25	50.92
Vertex Pharmaceuticals	$12.00B	9.20	$3.95B	$16.86	25.81

Intuitive Surgical has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

In the previous week, Vertex Pharmaceuticals had 19 more articles in the media than Intuitive Surgical. MarketBeat recorded 54 mentions for Vertex Pharmaceuticals and 35 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 1.51 beat Vertex Pharmaceuticals' score of 0.88 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	31 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vertex Pharmaceuticals	29 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Intuitive Surgical's net margin of 28.15%. Vertex Pharmaceuticals' return on equity of 23.86% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Intuitive Surgical presently has a consensus target price of $581.91, suggesting a potential upside of 38.53%. Vertex Pharmaceuticals has a consensus target price of $555.17, suggesting a potential upside of 27.58%. Given Intuitive Surgical's higher possible upside, research analysts plainly believe Intuitive Surgical is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.65
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Vertex Pharmaceuticals beats Intuitive Surgical on 11 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$110.45B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	25.81	15.19	20.66	25.69
Price / Sales	9.20	194.05	527.03	64.81
Price / Cash	24.45	56.93	27.81	36.27
Price / Book	5.92	6.94	9.77	6.74
Net Income	$3.95B	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	-0.25%	4.75%	6.33%	9.09%
1 Year Performance	2.32%	78.29%	41.88%	42.54%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	4.3713 of 5 stars	$435.17 +1.2%	$555.17 +27.6%	+1.1%	$110.45B	$12.00B	25.81	6,400	Earnings Report Analyst Upgrade Analyst Revision
AMZN Amazon.com	4.5462 of 5 stars	$271.90 +1.4%	$311.65 +14.6%	+41.2%	$2.92T	$716.92B	32.52	1,576,000	Trending News Analyst Revision
AXSM Axsome Therapeutics	3.3974 of 5 stars	$224.03 +8.5%	$235.79 +5.2%	+101.7%	$11.52B	$638.50M	N/A	380	Earnings Report High Trading Volume
CRSP CRISPR Therapeutics	2.614 of 5 stars	$53.58 +3.8%	$64.53 +20.4%	+53.9%	$5.17B	$3.51M	N/A	460	Earnings Report Analyst Upgrade
GOOG Alphabet	4.1006 of 5 stars	$379.64 -0.9%	$362.73 -4.5%	+157.2%	$4.59T	$402.84B	28.96	190,200	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Do analysts rate AMZN or VRTX?

Which has more risk & volatility, AMZN or VRTX?

Is AMZN or VRTX more profitable?

Does the media favor AMZN or VRTX?

Which has higher earnings & valuation, AMZN or VRTX?

Do insiders & institutionals have more ownership in AMZN or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Do analysts recommend VRTX or AXSM?

Which has more volatility and risk, VRTX or AXSM?

Is VRTX or AXSM more profitable?

Does the media favor VRTX or AXSM?

Which has better earnings and valuation, VRTX or AXSM?

Do institutionals & insiders have more ownership in VRTX or AXSM?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Do insiders and institutionals have more ownership in VRTX or CRSP?

Which has more risk and volatility, VRTX or CRSP?

Do analysts recommend VRTX or CRSP?

Does the media refer more to VRTX or CRSP?

Is VRTX or CRSP more profitable?

Which has preferable valuation & earnings, VRTX or CRSP?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Do insiders and institutionals have more ownership in VRTX or GOOG?

Which has more risk and volatility, VRTX or GOOG?

Do analysts recommend VRTX or GOOG?

Does the media refer more to VRTX or GOOG?

Is VRTX or GOOG more profitable?

Which has preferable valuation & earnings, VRTX or GOOG?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Which has higher valuation & earnings, ISRG or VRTX?

Which has more risk and volatility, ISRG or VRTX?

Does the media prefer ISRG or VRTX?

Do institutionals and insiders hold more shares of ISRG or VRTX?

Is ISRG or VRTX more profitable?

Do analysts rate ISRG or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools